Literature DB >> 9181380

Cytomegalovirus infection in newborns and their family members: polymerase chain reaction analysis of isolates.

I E Souza1, A Gregg, D Pfab, J D Dawson, P Benson, M E O'Neill, J R Murph, S J Petheram, J F Bale.   

Abstract

Polymerase chain reaction (PCR) analysis with primers for the pp65, a-sequence, glycoprotein B, and major immediate early genes of human cytomegalovirus (CMV) was used to study five congenitally-infected infants and their CMV-infected family members. Family members excreting CMV included three mothers and two siblings. The PCR results indicated that the CMV strain excreted by each infant was indistinguishable from that excreted by the corresponding family member. By contrast, the molecular profiles of the CMV strains were distinct between families, indicating that the PCR algorithm described in this study is a useful method for analyzing CMV strains.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9181380     DOI: 10.1007/BF02113601

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  16 in total

1.  Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes.

Authors:  S W Chou; K M Dennison
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

2.  Infectious Diseases Society of America and Centers for Disease Control. Summary of a workshop on surveillance for congenital cytomegalovirus disease.

Authors:  G J Demmler
Journal:  Rev Infect Dis       Date:  1991 Mar-Apr

Review 3.  Polymerase chain reaction: trenches to benches.

Authors:  D H Persing
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

4.  Differentiation of cytomegalovirus strains by restriction analysis of DNA sequences amplified from clinical specimens.

Authors:  S W Chou
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

5.  Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage.

Authors:  R R Spaete; R M Thayer; W S Probert; F R Masiarz; S H Chamberlain; L Rasmussen; T C Merigan; C Pachl
Journal:  Virology       Date:  1988-11       Impact factor: 3.616

6.  A prospective molecular epidemiological study of cytomegalovirus infections in two day care centers in Sweden: no evidence for horizontal transmission within the centers.

Authors:  L Grillner; K Strangert
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

7.  Young children as a probable source of maternal and congenital cytomegalovirus infection.

Authors:  R F Pass; E A Little; S Stagno; W J Britt; C A Alford
Journal:  N Engl J Med       Date:  1987-05-28       Impact factor: 91.245

8.  The occupational risk of cytomegalovirus infection among day-care providers.

Authors:  J R Murph; J C Baron; C K Brown; C L Ebelhack; J F Bale
Journal:  JAMA       Date:  1991-02-06       Impact factor: 56.272

9.  Analysis of acquired human cytomegalovirus infections by polymerase chain reaction.

Authors:  J F Bale; M E O'Neil; S S Fowler; J R Murph
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

10.  Comparative analysis of human cytomegalovirus a-sequence in multiple clinical isolates by using polymerase chain reaction and restriction fragment length polymorphism assays.

Authors:  J A Zaia; G Gallez-Hawkins; M A Churchill; A Morton-Blackshere; H Pande; S P Adler; G M Schmidt; S J Forman
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

View more
  2 in total

1.  Characterization of human cytomegalovirus strains by analysis of short tandem repeat polymorphisms.

Authors:  A Walker; S J Petheram; L Ballard; J R Murph; G J Demmler; J F Bale
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

2.  Application of UL144 molecular typing to determine epidemiology of cytomegalovirus infections in preterm infants.

Authors:  R Stranska; R Schuurman; M Toet; M Verboon-Maciolek; L S de Vries; A M van Loon
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.